In a session during the 2023 National Comprehensive Cancer Network Annual Conference, Deborah M. Stephens, DO, provided important updates to treatment recommendations for patients with chronic lymphocytic leukemia/small lymphocytic lymphoma, and identified key factors for selecting frontline and subsequent therapies, including immunoglobulin heavy chain variable gene status, 17p deletion/TP53 mutation status, age, patient comorbidities, and resistance mutations.
Acute lymphoblastic leukemia (ALL) is the most common cancer in pediatric patients, with an overall 5-year survival of >90%.1 The length of treatment for these patients is typically 2 to 3 years and involves several phases (induction, consolidation, and maintenance) and multiple forms of chemotherapy.
Enasidenib Monotherapy with Addition of Azacitidine in Nonresponders Effective in Older Patients with Newly Diagnosed, IDH2-Mutated AML
The HARMONY Alliance: Novel Insights into Genomic Classification and Prognosis in Acute Myeloid Leukemia
Characteristics and Prognostic Effects of IDH Mutations Across the Age Spectrum in AML: A Collaborative Analysis
Effect of Early Blood Counts on Response and Overall SurvEffect of Early Blood Counts on Response and Overall Survival Following Glasdegib + LDAC in Newly Diagnosed AMLival Following Glasdegib + LDAC in Newly Diagnosed AML
Venetoclax plus Standard Intensive AML Induction/Consolidation with FLAG-IDA in Patients with Newly Diagnosed or Relapsed/Refractory AML
Venetoclax + FLAG-IDA was effective, elicited deep responses, and had an acceptable safety profile across multiple AML subgroups, representing an attractive option for adverse-risk newly diagnosed and relapsed/refractory AML patients, and as a bridge to allo-SCT.
Clinical Outcomes for Treatment-Naïve Patients with AML Ineligible for Intensive Chemotherapy Receiving Azacitidine or Decitabine
An analysis of outcomes for patients with treatment-naïve AML ineligible for intensive chemotherapy receiving either azacitidine or decitabine in the ASTRAL-1 study showed no significant differences in complete response (CR), overall CR, overall survival, or safety.
SAL-DaunoDouble Trial Interim Analysis: Single versus Double Induction with 7+3 for Patients with Newly Diagnosed AML
he SAL-DaunoDouble trial interim analysis suggests that, in patients with acute myeloid leukemia (AML) who respond well to a first 7+3 induction cycle of cytarabine plus anthracycline, it may be possible to omit a second induction cycle if deemed high-risk.
Page 1 of 5
Results 1 - 10 of 49
Results 1 - 10 of 49